BIOS BioPlus Acquisition Corporation

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in BioScrip, Inc. to Contact the Firm

NEW YORK, NY--(Marketwired - Nov 1, 2013) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in BioScrip, Inc. ("BioScrip" or the "Company") (NASDAQ: BIOS) of the November 29, 2013 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against BioScrip and certain executives.

A complaint has been filed on behalf of all persons who purchased BioScrip securities between August 8, 2011 and September 20, 2013 (the "Class Period") in the Southern District of New York.

The complaint alleges that the Company and its executives violated federal securities laws with respect to its disclosures concerning its business, operations, and prospects.

Specifically, the action alleges that BioScrip issued false and/or misleading statements concerning (i) the improper distribution of its product Exjade through its specialty pharmacy division and (ii) the violation of certain federal and state laws and regulations.

On September 23, 2013, the Company announced that the U.S. Attorney's Office for the Southern District of New York issued a civil investigative demand and the New York State Attorney General's Medicaid Fraud Control Unit issued a subpoena regarding the distribution of Exjade by BioScrip's specialty pharmacy division. 

Following this news, the Company's stock declined $2.60 per share or 23% within two trading sessions, to close at $8.47 per share on September 24, 2013.

Request more information now by clicking here: www.faruqilaw.com/BIOS. There is no cost or obligation to you.

Take Action

If you invested in BioScrip stock or options between August 8, 2011 and September 20, 2013 and would like to discuss your legal rights, visit www.faruqilaw.com/BIOS. You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding BioScrip's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients. To keep track of the latest securities litigation news, follow us on Twitter at www.twitter.com/MergerActivity or on Facebook at www.facebook.com/FaruqiLaw.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

FARUQI & FARUQI, LLP 369 Lexington Avenue, 10th Floor New York, NY 10017 Attn: Richard Gonnello, Esq. Email Contact Francis McConville, Esq. Email Contact Telephone: (877) 247-4292 or (212) 983-9330